Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
OXiGENE Inc. (NASDAQ: OXGN) shares jumped 17.48 percent to close at $2.42 a share Tuesday. The stock traded between $2.09 and $2.45 on volume of 7.96 million shares traded. The company is scheduled to provide an update and corporate overview at the ROTH Capital Partners 26th Annual Growth Stock Conference on Wednesday, March 12 at 9:30 a.m. pacific time. Shares of OXiGENE are down approximately 4.0 percent year-to-date.
Get more information on OXiGENE and free access to the in-depth equity report at:
Senomyx Inc. (NASDAQ: SNMX) shares surged 17.22 percent to close at $11.03 a share Tuesday. The stock traded between $10.45 and $12.74 on volume of 4.61 million shares traded. The company announced that its new flavor ingredient Sweetmyx has been determined to be Generally Recognized As Safe by the FDA. Shares of Senomyx are up approximately 120.0 percent year-to-date.
Get more information on Senomyx and free access to the in-depth equity report at:
Sunshine Heart Inc. (NASDAQ: SSH) shares dropped 22.43 percent to close at $6.26 a share Tuesday. The stock traded between $6.26 and $7.70 on volume 1.83 million shares traded. The company reported a loss of $0.42 a share for the fourth quarter of 2013, which was above the consensus estimate of $0.40 a share. Shares of Sunshine Heart are down approximately 35.0 percent year-to-date.
Get more information on Sunshine Heart and free access to the in-depth equity report at:
Zogenix, Inc. (NASDAQ: ZGNX) shares spiked 11.82 percent to close at $4.54 a share Tuesday. The stock traded between $4.03 and $4.68 on volume 10.94 million shares traded. The company in its recent earnings report announced that it has expanded its sales force to 150 sales representatives. Shares of Zogenix are up approximately 30.0 percent year-to-date.
Get more information on Zogenix free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities